Multidisciplinary care and management of very low-risk prostate cancer.

Authors

null

Ayal A. Aizer

Harvard Radiation Oncology Program, Boston, MA

Ayal A. Aizer , Jonathan J. Paly , Anthony L. Zietman , Paul Linh Nguyen , Clair Beard , Sandhya K. Rao , Irving D. Kaplan , Andrzej Niemierko , Michelle S. Hirsch , Chin-Lee Wu , Aria F. Olumi , M. Dror Michaelson , Anthony Victor D'Amico , Jason Alexander Efstathiou

Organizations

Harvard Radiation Oncology Program, Boston, MA, Massachusetts General Hospital, Boston, MA, Dana-Farber Cancer Institute/Brigham and Women's Hospital/Harvard Medical School, Boston, MA, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, Beth Israel Deaconess Medical Center, Boston, MA, Brigham and Women's Hospital, Boston, MA, Department of Urology, Massachusetts General Hospital, Boston, MA, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA

Research Funding

No funding sources reported

Background: The National Comprehensive Cancer Network (NCCN) recommends active surveillance (AS) as the primary management option for patients with very low-risk prostate cancer (VLRPC) and an expected survival of <20 years. Factors associated with selection of AS are therefore of clinical importance. We hypothesized that care at a multidisciplinary clinic (MC), where multiple physicians simultaneously review each case, will be associated with increased rates of AS in men with VLRPC, including those with limited life expectancy. Methods: Of 630 patients with low-risk prostate cancer managed at one of three tertiary care centers in Boston, MA in 2009, 274 (43.5%) had VLRPC. Patients were either seen by one or more individual providers in sequential visits (N=178) or at an MC (N=96), in which concurrent consultation with two or more of the following specialties was obtained: urology, medical oncology, and radiation oncology. Results: Patients seen at an MC were more likely to select AS than those seen by individual providers (64% vs 30%, p<.001), an association which remained significant on multivariable logistic regression (OR=4.16, p<.001), see Table. When the analysis was limited to patients with an expected survival of <20 years based on the 2007 Social Security Life Table, this association remained highly significant (OR=5.19, p<.001). Conclusions: Multidisciplinary care is strongly associated with selection of AS, adherence to NCCN guidelines, and minimization of over-treatment in patients with VLRPC.

Multivariable logistic regression for choice of active surveillance.
Variable OR (95% CI) p
Age (per yr incr) 1.08 (1.03-1.13) <.001
Race (black vs white, ref=white) 1.87 (0.34-10.41) .47
Marital status (married vs single, ref=married) 1.95 (0.91-4.16) .09
Charlson score (0 vs ≥1, ref=0) 1.68 (0.84-3.37) .14
Family history (yes vs no, ref=no) 0.97 (0.46-2.02) .92
PSA (per ng/mL) 0.92 (0.77-1.10) .37
% positive cores (per 1% incr) 0.91 (0.85-0.98) .02
Greatest individual core involvement (per 1% incr) 0.95 (0.92-0.98) <.001
Mean experience of physicians met (per yr incr) 1.04 (1.00-1.07) .03
Multidisciplinary clinic (no vs yes, ref=no) 4.16 (1.98-8.75) <.001
Institution
1 1.0 (ref)
2 1.89 (0.76-4.73) .17
3 1.60 (0.64-4.01) .31

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr 55)

DOI

10.1200/jco.2013.31.6_suppl.55

Abstract #

55

Poster Bd #

D10

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Genitourinary Cancers Symposium

Disease progression and competing mortality for men undergoing active surveillance for low-risk prostate cancer.

First Author: Kripa Guram

Abstract

2023 ASCO Genitourinary Cancers Symposium

Patient opinions on controversies: In regard to low-risk prostate cancer, is Gleason 6 the old Gleason 5?

First Author: Howard Wolinsky

First Author: Nita Mukand

First Author: Juan Javier-Desloges